Biosignatures have raised a £3.5m led by ADV to transform the lives of millions of people by diagnosing serious medical conditions earlier than ever before.
The company discovers new blood tests and has developed a machine learning system which, alongside its powerful sample measurement system, is a disruptive and dramatically cost-effective step forward in the discovery of new clinical diagnostic tests.
25 years ago, GPs had just two blood tests they could use to see if a patient had cancer. Today, despite billions of pounds spent on medical research, they still only have those two tests. Biosignatures has solved the key problems in life science research that cause this dramatic lack of progress.
Using the investment, Biosignatures is embarking on a major journey that will, over several years, analyse hundreds of thousands of samples from biobanks, starting in the UK, with the goal of developing 20 novel diagnostic screening tests. All 20 tests could be performed on one blood sample and will be targeted at cancers and
dementias. The market for these tests starts at everyone 50 and over.
Biosignatures’ management team has a strong background in technology companies including having founded, built and sold Nonlinear Dynamics.
Dave Bramwell, co-founder and CTO of Biosignatures, said: “We have spent many years optimising and perfecting the large, high-quality data set production capability needed for the successful application of our advanced AI discovery systems. This work gives us confidence that the biosignatures we discover will translate and validate in the clinic.
“Further, the modified proteins we measure have been implicated over recent years as critical in many disease processes from cancer to dementia. These two key elements combine into a unique capability which places us at the forefront of the production of new clinically relevant early diagnostics – identified as a critical need for healthcare systems worldwide.”